Cutaneous HPV and alpha-mucosal 9-valent HPV sero-status associations

Imagem de Miniatura
Arquivos
art_RAHMAN_Cutaneous_HPV_and_alphamucosal_9valent_HPV_serostatus_associations_2017.PDF (149.75 KB)
Citações na Scopus
2
Tipo de produção
article
Data de publicação
2017
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
ELSEVIER SCIENCE BV
Autores
RAHMAN, Shams
GIULIANO, Anna R.
ROLLISON, Dana E.
PAWLITA, Michael
WATERBOER, Tim
PONCE, Eduardo Lazcano
Citação
PAPILLOMAVIRUS RESEARCH, v.4, p.54-57, 2017
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Seroepidemiology of human papillomaviruses (HPV) among men is poorly understood. We examined the association between seropositivity to cutaneous HPV and 9-valent HPV (9vHPV) types. Six hundred men were randomly selected from the HPV Infection in Men (HIM) Study. Archived serum specimens were tested for antibodies against 9vHPV types [low-risk (6/11) and high-risk (16/18/31/33/45/52/58)], and 14 cutaneous types, including beta-types 5/8/12/14/17/22/23/24/38/47, alpha-type-27, gamma-type-4, mu-type-1, and nu-type-41, using a GST L1-based multiplex serology assay. Risk factor data were collected through questionnaires. Logistic regression was used to evaluate associations between mucosal and cutaneous HPV types. Approximately 21% of men were positive for >= 1 cutaneous HPV type, and >= 1 nine-valent HPV vaccine type at the same time. Men who were seropositive for any-cutaneous HPV were nearly twice as likely to be seropositive for 9vHPV (adjusted odds ratio (AOR) = 1.97, 95% confidence interval (CI): 1.30-2.99), high-risk (AOR = 1.83; 95% CI: 1.04-3.20), low-risk (AOR = 1.92; 95% CI: 1.16-3.18), and four-valent, 4vHPV, (AOR = 2.01; 95% CI: 1.25-3.21). Type-specific cutaneous HPV seropositivity (types: 8/14/17/23/38/27/4/1) was also positively associated with seropositivity to 9vHPV, high-risk, and low-risk categories. These data indicate that exposure to cutaneous HPV and 9vHPV types is common. Future longitudinal studies are needed to assess the temporality of these associations.
Palavras-chave
HPV, Cutaneous HPV, 9-valent HPV vaccine types, HIM study, Seroepidemiology
URI
https://observatorio.fm.usp.br/handle/OPI/26915
Referências
  1. Campbell CMP, 2013, J CLIN VIROL, V58, P652, DOI 10.1016/j.jcv.2013.10.011
  2. Edelstein ZR, 2011, J INFECT DIS, V204, P209, DOI 10.1093/infdis/jir242
  3. Giuliano A. R., 2015, PAPILLOMAVIRUS RES
  4. Giuliano AR, 2008, CANCER EPIDEM BIOMAR, V17, P2036, DOI 10.1158/1055-9965.EPI-08-0151
  5. Giuliano AR, 2015, INT J CANCER, V136, P2752, DOI 10.1002/ijc.29082
  6. Giuliano AR, 2011, LANCET, V377, P932, DOI 10.1016/S0140-6736(10)62342-2
  7. Hsu JYC, 2009, J MED VIROL, V81, P1444, DOI 10.1002/jmv.21529
  8. Michael KM, 2008, PLOS PATHOG, V4, DOI 10.1371/journal.ppat.1000091
  9. Rahman S., 2016, PLOS ONE, V11
  10. Rahman S, 2016, J GEN VIROL, V97, P3291, DOI 10.1099/jgv.0.000620
  11. Sehr P, 2002, J VIROL METHODS, V106, P61, DOI 10.1016/S0166-0934(02)00134-9
  12. Stanley Margaret, 2010, Infect Agent Cancer, V5, P19, DOI 10.1186/1750-9378-5-19
  13. Waterboer T, 2008, BRIT J DERMATOL, V159, P457, DOI 10.1111/j.1365-2133.2008.08621.x
  14. Waterboer T, 2005, CLIN CHEM, V51, P1845, DOI 10.1373/clinchem.2005.052381

Coleções
Artigos e Materiais de Revistas Científicas - FM/MDR
Artigos e Materiais de Revistas Científicas - LIM/24